Bernstein Sticks to Their Hold Rating for Wendy's (WEN)
Don't Miss TipRanks' Half-Year Sale
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Gargiulo covers the Consumer Cyclical sector, focusing on stocks such as Starbucks, Chipotle, and CAVA Group, Inc.. According to TipRanks, Gargiulo has an average return of -0.6% and a 49.28% success rate on recommended stocks.
In addition to Bernstein, Wendy's also received a Hold from BTIG's Peter Saleh in a report issued yesterday. However, on the same day, Goldman Sachs maintained a Sell rating on Wendy's (NASDAQ: WEN).
Based on Wendy's' latest earnings release for the quarter ending March 30, the company reported a quarterly revenue of $219.51 million and a net profit of $39.23 million. In comparison, last year the company earned a revenue of $534.75 million and had a net profit of $41.99 million
Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of WEN in relation to earlier this year. Most recently, in May 2025, Kenneth M. Cook, the CFO of WEN bought 1,500.00 shares for a total of $17,025.00.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Radcom Ltd (RDCM) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic Partnerships ...
Release Date: August 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Radcom Ltd (NASDAQ:RDCM) reported a 19% year-over-year increase in revenue, reaching a new record of $17.7 million for Q2 2025. The company ended the quarter with over $100 million in cash and no debt, indicating strong financial health. Operating income increased by more than 50% compared to Q2 last year, with a non-GAAP operating margin extending to nearly 20% of revenue. Radcom Ltd (NASDAQ:RDCM) is actively expanding strategic partnerships, including collaborations with Nvidia and ServiceNow, to enhance its AI-driven solutions. The company is well-positioned in the growing 5G and AI markets, with significant customer engagement and ongoing market shifts supporting its growth outlook. Negative Points Radcom Ltd (NASDAQ:RDCM) did not receive a grant from the Israel Innovation Authority in Q2 2025, unlike the previous year. The company faces currency exchange risks, as 60% of its operating expenses are in shekels, and it does not currently hedge these expenses. There is uncertainty in the directed device satellite space, with potential opportunities still unclear in terms of capital allocation. The competitive environment remains challenging, with competitors trying to shift out of telcos while Radcom Ltd (NASDAQ:RDCM) continues to invest in innovation. Despite strong performance, the company anticipates a gradual increase in sales and marketing expenses to support a growing pipeline and expand its presence in high-value regions. Q & A Highlights Warning! GuruFocus has detected 1 Warning Sign with RDCM. Q: How is the partnership with service management system vendors like ServiceNow and AWS progressing? A: Benny Epstein, CEO: The partnership is going very well. We are co-developing and interconnecting our platforms. A few connectors are already in place, and we are building agent-to-agent use cases together. Q: With $100 million in cash on the balance sheet, how is Radcom planning to allocate capital? A: Benny Epstein, CEO: Our first priority is potential M&A. We are progressing with a few candidates and will decide on capital allocation based on this progress. Q: What percentage of growth over the next 18 months is expected from existing customer expansion versus new logos? A: Benny Epstein, CEO: We anticipate around two-thirds of growth from existing customers and one-third from new logos. Q: Can you provide insight into the revenue split between 5G and legacy networks? A: Benny Epstein, CEO: While 5G is growing, LTE networks are still operational and will remain for a few more years. 5G is our focus, but LTE will continue to contribute to revenue. Q: Are there any emerging opportunities in the directed device satellite space? A: Benny Epstein, CEO: There is an active opportunity with a certain customer, but their capital allocation is still unclear. We are monitoring their progress and participating in opportunities as they arise. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 minutes ago
- Yahoo
TAT Technologies Ltd (TATT) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market ...
Release Date: August 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points TAT Technologies Ltd (NASDAQ:TATT) achieved double-digit revenue growth for the fourth consecutive quarter, with an 18% increase in Q2 2025 compared to the same period last year. The company's gross profit increased by 35%, and the gross margin expanded by 320 basis points to 25.1%, reflecting improved operational efficiencies. TAT Technologies Ltd (NASDAQ:TATT) increased its long-term agreement value and backlog by $85 million to $524 million, enhancing long-term visibility. The company generated approximately $7 million in positive cash flow from operations during the quarter, demonstrating the strength of its business model. TAT Technologies Ltd (NASDAQ:TATT) successfully completed a public offering, welcoming new institutional investors and increasing financial flexibility for potential acquisitions. Negative Points The company experienced some weaknesses in MRO intake, which affected short-term visibility and created fluctuations in revenue. TAT Technologies Ltd (NASDAQ:TATT) faced challenges due to the strength of the Israeli shekel compared to the US dollar, resulting in increased costs and a reduction in net profit. The aviation sector's macroeconomic and operational headwinds continue to pose challenges, impacting the company's short-term outlook. There is ongoing volatility in the MRO market, with potential short-term fluctuations in intake affecting revenue consistency. The trading and leasing business remains lumpy and difficult to forecast, adding complexity to revenue predictions. Q & A Highlights Warning! GuruFocus has detected 1 Warning Sign with TATT. Q: Can you elaborate on the MRO acceleration comments? Is the recovery broad-based or specific to certain markets? A: (Unidentified_2, CEO) The MRO market is experiencing volatility similar to past trends. Airlines initially reduce MRO work to save cash, leveraging spare inventory. However, as aircraft continue flying, especially older fleets, demand eventually rebounds. This recovery is not specific to any market but is a general trend observed over time. Q: What drove the strong cash flow in the quarter, and how do you view working capital growth going forward? A: (Unidentified_2, CEO) The company has focused on revenue growth, profitability, and now cash flow management. Improved collections and tighter controls have contributed to positive cash flow. We are well-positioned with the right inventories to support market demand and will continue to manage cash flow effectively. Q: How is the APU strategy progressing, particularly with smaller deals and moving upmarket? A: (Unidentified_2, CEO) The APU strategy is progressing well. We are capturing more market share in historical fleets and winning smaller RFPs on new platforms. This approach is promising and reflects in the growth of our backlog and long-term agreements. Q: Can you provide more color on the current dynamics in the APU market, especially regarding spares and maintenance? A: (Unidentified_2, CEO) The APU market is global, with airlines maintaining spare engines to manage short-term needs. Typically, airlines do not perform minimal repairs but wait until spare pools are low before sending engines for full repair. This behavior leads to fluctuations in demand. Q: Regarding M&A, are there specific capabilities or products you are targeting to expand your portfolio? A: (Unidentified_2, CEO) We aim to stay close to our existing capabilities while expanding into more mechanical systems and components. Our strategy focuses on being meaningful to customers by consolidating vendor lists and adding capabilities, particularly in MRO and OEM areas. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
30 minutes ago
- Yahoo
FDA Approval and Strategic Deals Drive Apellis Pharmaceuticals' Stock Higher for the Week
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one of the . The company's weekly stock price performance surges following FDA approvals for EMPAVELI, second-quarter 2025 financial results, and capped royalty purchase agreements. A biomedical scientist in a lab coat conducting research on biopharmaceutical compounds. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), headquartered in Massachusetts, is a global biopharmaceutical enterprise advancing treatments for diseases through complement system modulation. The company has pioneered first-in-class C3-targeting therapies for conditions such as geographic atrophy, rare kidney disorders, and PNH. On July 28, 2025, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) received U.S. FDA approval for EMPAVELI for the treatment of patients 12 years and older with C3 glomerulopathy (C3G) and primary immune complex glomerulonephritis (IC-MPGN). With this approval, EMPAVELI becomes the first and only FDA-approved treatment for primary IC-MPGN, adolescent patients with C3G, and post-transplant C3G disease recurrence, thus capturing the unmet demands for the drug. On July 31, 2025, the company reported its Q2 2025 financial results, showing $178.5 million in total revenues. SYFOVRE U.S. net product revenue reached $150.6 million, with demand growing 6% quarter-over-quarter, maintaining its market leadership in GA. In the report, the company also highlighted a capped royalty purchase agreement with Sobi, under which it would receive up to $300 million for 90% of ex-U.S. royalties of Aspaveli, including an upfront cash payment of $275 million. With this, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) focuses on pipeline development and commercial expansion without immediate financial pressure. Following these developments, the stock price went up 27.70% this week, making a turnaround from its 32.78% yearly loss and drawing interest from traders eyeing biotech bounce-backs. While we acknowledge the potential of APLS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None.
